Anorexia Nervosa Has Cancer-Level Mortality. With No Targeted Therapy.
Society still treats anorexia and compulsive behaviors as choices, not biological illnesses, leaving patients misunderstood, stigmatized, and without the targeted medical care they deserve.
Our founders uncovered a critical dopamine imbalance in the striatum, a neural pathway central to habit and compulsion. When disrupted, this circuitry overrides conscious control, narrowing behavior into rigid patterns that feel automatic and inescapable. By restoring balance within this pathway, compulsive drive decreases. This insight transforms anorexia from a disorder managed behaviorally into one with a clear biological target.
- 01Actively transported across the blood-brain barrier
- 02Inactive outside the brain = fewer peripheral side effects
- 03Composition-of-matter IP across two molecular classes
Translational Science With a Defined Biological Target.
Our program combines preclinical validation, human signal, and molecular redesign.
Together they represent a rare convergence in early CNS development: validated biology, human signal, optimized chemistry, and secured funding.
- 01Pre-clinical validation in mice
- 02Pre-clinical validation in human
- 03IP for new drug class patented and licensed
- 04Research grant awarded by Quebec Consortium for Drug Discovery
- Initial Market
- Anorexia Nervosa
- Pipeline Opportunities
- Obsessive compulsive disorder
- Phone / social media addiction
- Gambling addiction
- Tics / Tourette’s
- BFRB’s
- Rigid behaviors in autism
- Other eating disorders
We are beginning with anorexia nervosa, a profoundly underserved condition that offers a focused entry into a high-need, orphan therapeutic category. The underlying biology is shared across a broader family of compulsive disorders, creating the potential to extend this approach by targeting the neural circuitry that drives habit and compulsion.
We are living in a moment of profound misunderstanding.
A time when biology is mistaken for behavior.
Where patients are blamed for the very behaviors that bind them.
For decades, psychiatric medicine has asked people to try harder.
To eat more.
To stop.
To resist.
To choose.
But choice disappears when biology takes over.
And nowhere is that more devastating than in anorexia nervosa.
We believe in a different future.
A future where science restores what stigma stole.
Where medicine honors the complexity of the human brain.
Where patients are seen, believed, and treated with precision.
Our work begins with the first targeted medicine ever created for anorexia nervosa.
A compound that activates only where it should, inside the brain. A molecule that restores the space between impulse and intention. Between compulsion and control. Between survival and possibility.
We do not exist to manage symptoms.
We exist to return agency.
To transform what is possible.
To give people back their lives.
This is more than medicine.
This is the reclamation of choice.
The target is defined.
The asset is built.
The path is clear.
For investor inquiries:
Headquarters
Montreal